CompletedPhase 3

Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia

Egypt192 participantsStarted 2018-06-01

Plain-language summary

This study aimed to determine the role of oral zinc in reducing the neonatal indirect hyperbilirubinemia if used concomitant with the standard phototherapy

Who can participate

Age range1 Hour – 28 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Neonates with total serum bilirubin (TSB) exceeding the 40th percentile track for age as per the hour-specific bilirubin nomogram of the American Academy of Pediatrics (AAP) * Neonates who have indirect hyperbilirubinemia, not indicated for exchange transfusion. Exclusion Criteria: * Neonates submitted to blood transfusion. * Neonates indicated for exchange transfusion * Associated congenital anomalies. * Co-morbidities such as sepsis, pneumonia or respiratory distress. * Neonates whom their mothers received phenobarbitone during the third trimester

What they're measuring

Determine the role of oral zinc in reducing level of unconjugated hyperbilirubinemia

Timeframe: Baseline

Trial details

NCT IDNCT06227624

SponsorNational Liver Institute, Egypt

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-06-01

View on ClinicalTrials.gov More Neonatal Jaundice trials